Antiobesity Market Analysis Covering Growth Drivers And Future Outlook

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Large Will The Antiobesity Market Be By 2030 Compared To Its 2026 Market Size?

The antiobesity market has experienced robust expansion in recent years. Its valuation is anticipated to climb from $4.1 billion in 2025 to $4.47 billion by 2026, reflecting a compound annual growth rate (CAGR) of 9.0%. The market’s historical growth can be linked to several factors, including the escalating global obesity rates, the limited efficacy of interventions solely based on lifestyle, the availability of appetite suppressants, the increasing prevalence of metabolic disorders, and weight management strategies guided by physicians.

The antiobesity market is projected to experience substantial expansion in the coming years. This market is anticipated to reach $6.56 billion by 2030, driven by a compound annual growth rate (CAGR) of 10.0%. This expansion during the forecast period stems from factors such as the rising incidence of diabetes and obesity, advancements in hormone-based medications, broader reimbursement coverage, heightened awareness regarding obesity, and the need for long-term effective weight loss strategies. Key developments expected in this period encompass the swift uptake of glp-1 based treatments, a growing inclination towards prescribed weight loss medications, the increased application of combined antiobesity treatments, a stronger emphasis on managing weight over extended periods, and greater availability of obesity care.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3403&type=smp

What Major Factors Are Driving The Antiobesity Market Forward?

The increasing incidence of obesity is expected to fuel the expansion of the anti-obesity drugs market in the future. This chronic metabolic disorder involves the buildup of excessive body fat, elevating the risk of severe health issues such as diabetes, cardiovascular diseases, osteoarthritis, and specific cancers. The growing prevalence of obesity stems from increased intake of ultra-processed foods rich in sugars, unhealthy fats, and refined carbohydrates, coupled with inactive lifestyles that limit physical movement. This heightened prevalence of obesity underscores the demand for efficacious antiobesity medical solutions, complementary weight management treatments, and sustained therapeutic options to lessen related health dangers and enhance patient results. As an illustration, in March 2024, the World Obesity Federation, a UK-based body dedicated to obesity research and advocacy, projected that 79% of adults with overweight and obesity and 88% of children with overweight and obesity will reside in low and middle income countries by 2035. Consequently, the escalating prevalence of obesity is propelling the anti-obesity drugs market’s growth.

What Are The Main Segments Within The Antiobesity Market Segment Structure?

The antiobesity market covered in this report is segmented –

1) By Drug Class: Peripherally Acting Anti-Obesity Drugs, Centrally Acting Anti-Obesity Drugs

2) By Type: Prescription Drugs (Rx), OTC Drugs

3) By Medication: Monotherapies, Polytherapies

Subsegments:

1) By Peripherally Acting Anti-Obesity Drugs: Orlistat, Lorcaserin

2) By Centrally Acting Anti-Obesity Drugs: Phentermine, Topiramate, Naltrexone-Bupropion Combination, Liraglutide

What Market Trends Are Affecting The Antiobesity Market?

Leading companies in the antiobesity market are concentrating on product innovation and new formulations, such as dual glucose-dependent insulinotropic peptide receptor agonists, to offer more effective weight loss, enhanced metabolic outcomes, and better tolerability. These treatments utilize synergistic actions on appetite suppression, insulin sensitivity, and energy expenditure to provide superior efficacy compared to earlier generation GLP-1-only treatments. For instance, in December 2024, Eli Lilly, a US-based pharmaceutical company, secured FDA approval for Zepbound (tirzepatide), establishing it as the first and only prescription dual GIP/GLP-1 agonist authorized for chronic weight management. Tirzepatide has exhibited robust weight-loss efficacy, with phase 3 trial participants achieving significant reductions in body weight. With its expanded indication, Zepbound is projected to solidify Lilly’s leadership in the precision obesity therapy space, meeting the escalating demand for long-acting, high-efficacy treatments.

Who Are The Companies Participating In The Antiobesity Market?

Major companies operating in the antiobesity market are Takeda Pharmaceutical Company Limited, Eisai Co. Ltd., Novo Nordisk A/S, Zafgen Inc., Rhythm Pharmaceuticals Inc., Zydus Cadila, Norgine B.V., Vivus Inc., Arena Pharmaceuticals Inc., Orexigen Therapeutics Inc., Eli Lilly and Company, Amgen Inc., AstraZeneca PLC, Viking Therapeutics Inc., Structure Therapeutics Inc., Gelesis Inc., Sanofi S.A., F. Hoffmann-La Roche Ltd, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Cipla Ltd., Lupin Ltd., Torrent Pharmaceuticals Ltd.

Get The Full Antiobesity Market Report:

https://www.thebusinessresearchcompany.com/report/antiobesity-global-market-report

Which Region Leads The Antiobesity Market In Overall Market Size?

North America was the largest region in the anti-obesity market in 2025. Middle East is expected to be the fastest-growing region in the antiobesity market. The regions covered in the antiobesity market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Antiobesity Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/antiobesity-global-market-report

Browse Through More Reports Similar to the Global Antiobesity Market 2026, By The Business Research Company

Antiobesity Market Report 2026

https://www.thebusinessresearchcompany.com/report/antiobesity-global-market-report

Antimony Market Report 2026

https://www.thebusinessresearchcompany.com/report/antimony-global-market-report

Antivenom Market Report 2026

https://www.thebusinessresearchcompany.com/report/antivenom-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795